Related Experiment Video
Updated: Sep 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Reshaping Dyslipidaemia Treatment with Bempedoic Acid-A Narrative Review
Dominik Strikic1, Zvonimir Begic2, Ivana Radman3
1Division of Clinical Pharmacology, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia.
Insights
Bempedoic acid effectively lowers LDL-C and reduces cardiovascular events in statin-intolerant patients. Combination therapy with ezetimibe enhances efficacy, but monitoring for side effects like increased uric acid is crucial.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Dyslipidaemia is a primary driver of atherosclerotic cardiovascular disease (ASCVD).
- Statins are standard therapy, but many patients experience intolerance or suboptimal low-density lipoprotein cholesterol (LDL-C) levels.
- Alternative lipid-lowering agents are needed for effective ASCVD risk reduction.
Purpose of the Study:
- To review the pharmacological profile and clinical efficacy of bempedoic acid.
- To evaluate bempedoic acid's role in managing dyslipidaemia, particularly in statin-intolerant patients.
- To synthesize current evidence on bempedoic acid and identify future research directions.
Main Methods:
- Review of recent clinical trials, including the CLEAR Outcomes Study.
- Analysis of bempedoic acid's mechanism of action as an ATP citrate lyase inhibitor.
- Comparative synthesis of efficacy data, including combination therapy with ezetimibe.
Main Results:
- Bempedoic acid demonstrated a significant reduction in LDL-C (approx. 29 mg/dL).
- The CLEAR Outcomes Study showed a 13% reduction in major adverse cardiovascular events (MACEs) in statin-intolerant patients.
- Combination therapy with ezetimibe further improved lipid-lowering effects.
Conclusions:
- Bempedoic acid offers a valuable therapeutic option for lowering LDL-C and reducing cardiovascular risk in statin-intolerant individuals.
- Careful patient selection and monitoring are necessary due to potential adverse effects, such as elevated uric acid and gout.
- Further research is needed to fully elucidate bempedoic acid's long-term benefits and optimal use in diverse patient populations.
Abstract:
Dyslipidaemia is one of the main causes of atherosclerotic cardiovascular disease (ASCVD) worldwide. Although statins remain the cornerstone of lipid-lowering therapy, many patients do not achieve optimal target levels of low-density lipoprotein cholesterol (LDL-C) due to intolerance or inadequate response. Bempedoic acid, an oral ATP citrate lyase inhibitor, provides a liver-specific mechanism that lowers LDL-C levels while minimising muscle-related side effects. Recent clinical trials, including the CLEAR Outcomes Study, have shown that bempedoic acid was able to reduce LDL-C by approximately 29 mg/dL and major adverse cardiovascular events (MACEs) by 13% in patients intolerant to statins. Combination therapy with ezetimibe further enhances this effect. However, adverse effects such as increased uric acid and gout have been reported, requiring careful patient selection and continuous monitoring. This review provides a comparative synthesis of the latest evidence on bempedoic acid, including its pharmacological profile, its efficacy in different patient groups, and its place within current treatment strategies for dyslipidaemia. It also identifies research gaps and directions for future studies.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...